Welcome to the Andean Pacific HIV Clinical Forum website!
The 1st Andean Pacific HIV Clinical Forum on Integrase Inhibitors will be held on 29 June, 2017 in Santiago, Chile, just prior to our 1st Andean Pacific Workshop on HIV & Hepatitis (30 June – 1 July 2017).
This program is an abstract-driven scientific & educational program dedicated to the integration of science and clinical practice focusing on Integrase Inhibitors.
By joining us, you will be updated on the latest developments related to Integrase, and will be provided with a platform to share your clinical experience. The program will include plenary lectures, Q&A and debate, stimulating interaction in order to bridge the knowledge gap between experts and the HIV treatment community.
This Forum offers a unique platform for discussion on the clinical utility of Integrase Inhibitors in daily practice. After your participation in the meeting, you will be able to:
identify and manage patients who would be eligible for induction-maintenance therapy;
recognize potential drug interactions and, based on this knowledge, develop treatment strategies that could prevent these interactions;
design treatment strategies for different patient populations;
describe and identify the various factors that influence the use of long acting antivirals.
Who should attend?
If you are doing research on or have clinical experience with Integrase Inhibitors or if you are interested in learning more about using Integrase Inhibitors in daily practice, please join us on 29 June, 2017 in Santiago, Chile.
Sheraton Hotel & Convention Center
Sta María 1742, Santiago, Providencia, Región Metropolitana, Chili
Phone: +56 2 2233 5000
We look forward to welcoming you to the meeting in Santiago!
The Program Chairs
Charles Boucher, MD, PhD
Jonathan Schapiro, MD
Carlos Beltrán, MD
Thursday 29 June
|08.00h||Registration & Welcome coffee|
|08.30h||Welcome, Introductions and Goals
Chilean AIDS Cohort (ChiAC), Santiago, Chile
|08.45h||Resistance Characteristics of Integrase Inhibitors
Erasmus Medical Center, Rotterdam, The Netherlands
|09.30h||Transmitted and Acquired HIV Drug Resistance in Latin America
Luis Enrique Soto Ramirez
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico
|10:45h||The use of Integrase Inhibitors in Latin America: From guidelines to the Real World
Universidad del Valle, Cali, Colombia
|11.15h||PEP after sexual exposures
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Infected Chilean Patients. Frequency and Evolution between 2013 and 2016.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) compared with Ritonavir boosted Atazanavir (ATV/r) plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): Subgroup analyses
Chilean AIDS Cohort (ChiAC), Santiago, Chile
|14.30h||Optimizing use of HIV Diagnostic Technologies in Latin America
NIFESP Laboratorio de Retrovirologia, São Paulo, Brazil
HIV Proviral DNA is an adequate genetic compartment for detection of resistance mutations associated to integrase inhibitors (INIs) therapy in patient with undetected or low viral load.
|16.00h||Reduced Drug Regimens
Fundación Huésped, Buenos Aires, Argentina
|16.45h||Round Table Discussion: Future of Integrase Inhibitors in Latin America
|17.30h||End of Meeting|
| Networking Dinner
Don’t miss out and register for the exciting 1st Andean Pacific HIV Clinical Forum meeting in Santiago, Chile! Use the “Register Here” button at the bottom of this page.
Registration is free of charge for Healthcare Practitioners.
| Registration fees
|Healthcare practitioners*||Free registration|
| Sponsoring Industry
|10 free registration slots|
|Additional registrations||EUR 595|
*Healthcare practitioners are defined as professionals that provide any type of health care service to HIV-infected patients. If you are not sure, please do not hesitate to contact the Conference Secretariat.
**Non-HCPs are defined as individuals not providing any healthcare service to patients or are part of a commercial pharma company
***Industry is defined as representatives of a commercial institute that do not financially support this workshop (you can find an overview of the workshop sponsors on the workshop website).
***Sponsoring Industry is defined as representatives of a commercial institute that financially support this workshop (you can find an overview of the workshop sponsors on the workshop website).
Registration does not include accommodation. Should you require accommodation, please contact the Conference Secretariat at firstname.lastname@example.org.
REGISTRATION IS LIMITED!
– We strongly suggest that you register early to ensure your spot at the meeting, as registration will no longer be possible when the capacity of the venue is reached.
– Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when a confirmation of your registration has been sent.
Abstract submission: CLOSED
Abstracts should contain the following four components (please bold the four section headings noted below within the text of your abstract submission):
Background: a concise statement of the issue under investigation or a hypothesis;
Materials & Methods: the experimental methods used (including the statistical analyses employed);
Results: specific findings (promises such as “to be completed” or “to be presented” are not acceptable);
Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as “the results will be discussed” are not acceptable).
Please note that abstracts cannot be accepted if tables, graphs, grant acknowledgements or literature references are included. The maximum word count for the abstract body is 500 words.
Abstracts are considered official communications to the conference and will be treated confidentially.
Submitters of acccepted abstracts agree to attend the meeting and present their abstract as scheduled.
Categories for abstract submission
For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.
We encourage you to submit your abstracts
on the following topics:
– Basic Virology
– Pharmacology and Drug interactions
– Adverse Events and Toxicity
– Clinical Trials
– Informative case reports
Abstract submission & Deadline
Authors can submit their abstracts electronically until 28 April 2017 using the “Submit Abstract” button at the bottom of this page. This will direct you to the appropriate webpage. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Notification of abstract acceptance and presentation format
Notifications of acceptance and format of presentation (oral or poster presentation) will be e-mailed to submitting authors within two weeks after the abstract submission deadline. It is the responsibility of the corresponding/presenting author to inform all co-authors of the abstract’s status.
Please notify the Conference Secretariat if you have not received notification by mid-May.
If an abstract is accepted, one author is required to register for the conference and present the paper as scheduled.
Abstract Submitter’s Registration Guidelines will be sent together with the notification. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.
Accepted abstracts will be published in the Conference Abstract Book, which will be distributed during the conference. In addition, all abstracts will be published in the journal “Reviews in Antiviral Therapy & Infectious Diseases”. Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.
ABSTRACT SUBMISSION CLOSED
Financial backing from the corporate community will help us deliver an impactful and essential meeting experience. This collaboration plays a vital for both the organizational as well as the scientific success of the program.
Your financial support will help advance the field significantly by providing healthcare professionals with a platform to present findings, discuss conclusions, and create strategies for the future.
Show your commitment to the cause and get in touch with us for a tailored support package, please contact Alice Posthumus-Plantinga at email@example.com or call +31 6 224 82 179.
The 1st AndeanPacific HIV Forum meeting: Integrase Inhibitors is generously supported by an unrestricted educational grant from ViiV Healthcare.
The 1st Andean Pacific HIV Clinical Forum is looking for endorsers. Your support and collaboration play a key role to this meeting’s success. Members of the endorsing organizations receive a 25% discount on registration fees. Get in touch with us if you want your organization to be part of the Andean Pacific HIV Clinical Forum at firstname.lastname@example.org.
Accreditation will be applied for at the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS).
Accreditation will also be applied for at the Sida Chile Corporation.
Phone: +56 2 2233 5000.
The meeting will take place just prior to the 1st Andean Pacific Workshop on HIV & Hepatitis (30 June & 1 July).